Faraz Ali - 10 Sep 2026 Form 4 Insider Report for Tenaya Therapeutics, Inc. (TNYA)

SEC form
4
Accepted by SEC
11 Sep 2026, 20:10:47 UTC
Prior SEC filing
17 Aug 2026
Next SEC filing
18 Nov 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Faraz Ali filed Form 4 for Tenaya Therapeutics, Inc. (TNYA) on 11 Sep 2026.

Key facts

  • This page summarizes Faraz Ali's Form 4 filing for Tenaya Therapeutics, Inc. (TNYA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 11 Sep 2026, 20:10.

Change

  • Previous filing in this sequence was filed on 17 Aug 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001667937 Primary reporting owner

Ali Faraz

Relationship
Chief Executive Officer, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNYA transaction

Common Stock

Award

Transaction value
Shares
+122,000
Change %
+29%
Price
$0.000000*
Shares after
539,782
Date
10 Sep 2026
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNYA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares
+732,500
Change %
Price
$0.000000*
Shares after
732,500
Date
10 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
732,500
Exercise price
$0.6488
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

Footnote F2

The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.

Footnote F3

Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

Footnote F4

Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .